癌症预防剂发展的新趋势。

IF 2.5 Q3 ONCOLOGY Journal of Cancer Prevention Pub Date : 2023-03-30 DOI:10.15430/JCP.2023.28.1.24
Mark Steven Miller, Altaf Mohammed
{"title":"癌症预防剂发展的新趋势。","authors":"Mark Steven Miller,&nbsp;Altaf Mohammed","doi":"10.15430/JCP.2023.28.1.24","DOIUrl":null,"url":null,"abstract":"<p><p>Advances in omics and immunology over the past 20 years have revolutionized the approach to cancer prevention, with the goal now focused on identifying populations at higher risk for developing cancer in their lifetime as a result of either extensive exposure to environmental carcinogens or harboring precancer lesions or inherited genetic mutations that predispose them to specific types of cancer(s). Thus, the naïve idea that cancer could be \"prevented\" in the general population has evolved to a more practical approach based on the understanding that the target population for preventive agents will be individuals who already have alterations, in gene pathways, whether inherited or environmentally caused, and the goal will be to \"intercept\" these lesions at the earliest stages in the path from an initial genetic lesion to full-blown cancer. The Division of Cancer Prevention of the National Cancer Institute and the Office of Disease Prevention at the National Institutes of Health recently sponsored the second biennial \"Translational Advances in Cancer Preventive Agent Development Meeting,\" held virtually from September 7-9th. In this Meeting Report, we highlight the scientific sessions of this meeting that covered the most recent advances in preventive agent development that also highlighted these rapidly emerging trends in this research area.</p>","PeriodicalId":15120,"journal":{"name":"Journal of Cancer Prevention","volume":"28 1","pages":"24-28"},"PeriodicalIF":2.5000,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8c/b3/jcp-28-1-24.PMC10080017.pdf","citationCount":"0","resultStr":"{\"title\":\"Emerging Trends in Cancer Prevention Agent Development.\",\"authors\":\"Mark Steven Miller,&nbsp;Altaf Mohammed\",\"doi\":\"10.15430/JCP.2023.28.1.24\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Advances in omics and immunology over the past 20 years have revolutionized the approach to cancer prevention, with the goal now focused on identifying populations at higher risk for developing cancer in their lifetime as a result of either extensive exposure to environmental carcinogens or harboring precancer lesions or inherited genetic mutations that predispose them to specific types of cancer(s). Thus, the naïve idea that cancer could be \\\"prevented\\\" in the general population has evolved to a more practical approach based on the understanding that the target population for preventive agents will be individuals who already have alterations, in gene pathways, whether inherited or environmentally caused, and the goal will be to \\\"intercept\\\" these lesions at the earliest stages in the path from an initial genetic lesion to full-blown cancer. The Division of Cancer Prevention of the National Cancer Institute and the Office of Disease Prevention at the National Institutes of Health recently sponsored the second biennial \\\"Translational Advances in Cancer Preventive Agent Development Meeting,\\\" held virtually from September 7-9th. In this Meeting Report, we highlight the scientific sessions of this meeting that covered the most recent advances in preventive agent development that also highlighted these rapidly emerging trends in this research area.</p>\",\"PeriodicalId\":15120,\"journal\":{\"name\":\"Journal of Cancer Prevention\",\"volume\":\"28 1\",\"pages\":\"24-28\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2023-03-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8c/b3/jcp-28-1-24.PMC10080017.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cancer Prevention\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15430/JCP.2023.28.1.24\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15430/JCP.2023.28.1.24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

在过去的20年里,组学和免疫学的进步已经彻底改变了癌症预防的方法,现在的目标是确定由于广泛暴露于环境致癌物或隐藏癌前病变或遗传基因突变而导致其易患特定类型癌症的高危人群。因此,naïve认为癌症可以在普通人群中“预防”的想法已经发展成为一种更实用的方法,这种方法基于这样一种认识,即预防药物的目标人群将是那些在基因通路中已经发生改变的个体,无论是遗传的还是环境引起的,目标将是在从最初的遗传病变到全面癌症的早期阶段“拦截”这些病变。美国国家癌症研究所癌症预防部和国立卫生研究院疾病预防办公室最近主办了第二届两年一次的“癌症预防剂开发的转化进展会议”,该会议于9月7日至9日举行。在本会议报告中,我们重点介绍了本次会议的科学会议,这些会议涵盖了预防药物开发的最新进展,也突出了这一研究领域中迅速出现的趋势。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Emerging Trends in Cancer Prevention Agent Development.

Advances in omics and immunology over the past 20 years have revolutionized the approach to cancer prevention, with the goal now focused on identifying populations at higher risk for developing cancer in their lifetime as a result of either extensive exposure to environmental carcinogens or harboring precancer lesions or inherited genetic mutations that predispose them to specific types of cancer(s). Thus, the naïve idea that cancer could be "prevented" in the general population has evolved to a more practical approach based on the understanding that the target population for preventive agents will be individuals who already have alterations, in gene pathways, whether inherited or environmentally caused, and the goal will be to "intercept" these lesions at the earliest stages in the path from an initial genetic lesion to full-blown cancer. The Division of Cancer Prevention of the National Cancer Institute and the Office of Disease Prevention at the National Institutes of Health recently sponsored the second biennial "Translational Advances in Cancer Preventive Agent Development Meeting," held virtually from September 7-9th. In this Meeting Report, we highlight the scientific sessions of this meeting that covered the most recent advances in preventive agent development that also highlighted these rapidly emerging trends in this research area.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
4.00%
发文量
32
期刊最新文献
Anticancer Activity of Phytochemicals of the Papaya Plant Assessed: A Narrative Review. Kaempferol Synergistically Enhances Cisplatin-induced Apoptosis and Cell Cycle Arrest in Colon Cancer Cells. Recommendations for Healthy Lifestyle for Cancer Prevention and Healthy Aging. Elevated N1-Acetylspermidine Levels in Doxorubicin-treated MCF-7 Cancer Cells: Histone Deacetylase 10 Inhibition with an N1-Acetylspermidine Mimetic. Ribosomal Protein L9 Maintains Stemness of Colorectal Cancer via an ID-1 Dependent Mechanism.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1